Compounds > thioacetanilide
Page last updated: 2024-12-09

thioacetanilide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

thioacetanilide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID820777
CHEMBL ID3740596
SCHEMBL ID340780
SCHEMBL ID14160916
MeSH IDM0118568

Synonyms (34)

Synonym
l9al2go03y ,
unii-l9al2go03y
n-phenylthioacetamide
ethanethioamide, n-phenyl-
637-53-6
nsc-36984
usaf ek-1902
thioacetanilide
acetanilide, thio-
nsc36984
wln: suy1&mr
einecs 211-288-4
nsc 36984
ai3-00235
brn 2205727
AQ-012/40221353
n-phenylethanethioamide
thioacetanilide, 98%
FT-0693782
T0188
thioacetanilide [inci]
SCHEMBL340780
SCHEMBL14160916
DTXSID1060920
n-phenylethanethioamide #
AKOS025117063
CHEMBL3740596 ,
mfcd00004942
bdbm50499816
AS-41624
Q27282872
n-phenyl-thioacetamide
SB75793
CS-0107756

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Extensive SAR investigation led to potent compounds, with nanomolar activity on K103N, and orally bioavailable in rats."( Tetrazole thioacetanilides: potent non-nucleoside inhibitors of WT HIV reverse transcriptase and its K103N mutant.
Kinzel, OD; Laufer, R; Miller, MD; Moyer, G; Munshi, V; Muraglia, E; Orvieto, F; Palumbi, MC; Pescatore, G; Rowley, M; Summa, V; Williams, PD, 2006)		0.74

Dosage Studied

ExcerptRelevanceReference
" Following intragastric dosage (100 mg/kg), over 90% dose was excreted in urine, predominantly as conjugated metabolites: less than 7% was recovered in the faeces, consisting of unchanged thioacetanilide."( The metabolism of thioacetanilide in the rat.
Trennery, PN; Waring, RH, 1983)		0.79
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)4.10000.03403.987110.0000AID1265266
Polyphenol oxidase 2Agaricus bisporusKi1.20000.00063.28838.8900AID1265267
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Taste receptor type 2 member 38Homo sapiens (human)EC50 (µMol)18.00000.00491.36102.3000AID1619468
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Taste receptor type 2 member 38Homo sapiens (human)Activity3.00000.15003.256310.0000AID1619467
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
detection of chemical stimulus involved in sensory perception of bitter tasteTaste receptor type 2 member 38Homo sapiens (human)
G protein-coupled receptor signaling pathwayTaste receptor type 2 member 38Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityTaste receptor type 2 member 38Homo sapiens (human)
bitter taste receptor activityTaste receptor type 2 member 38Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneTaste receptor type 2 member 38Homo sapiens (human)
membraneTaste receptor type 2 member 38Homo sapiens (human)
membraneTaste receptor type 2 member 38Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID1265274Inhibition of tyrosinase in mouse B16F10 cell lysates using DOPA as substrate relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265267Competitive inhibition of mushroom tyrosinase using L-tyrosine as substrate by Lineweaver-Burk plots analysis2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265270Cytotoxicity against mouse B16F10 cells assessed as cell survival at 50 uM after 48 hrs by MTT assay2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265272Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 20 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265266Inhibition of mushroom tyrosinase using L-tyrosine as substrate2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265271Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 10 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265269Binding affinity to mushroom tyrosinase assessed as fluorescence quenching2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
AID1265273Inhibition of tyrosinase in mouse B16F10 cells assessed as reduction of melanin production at 50 uM relative to control2015European journal of medicinal chemistry, Dec-01, Volume: 106Analogues of ethionamide, a drug used for multidrug-resistant tuberculosis, exhibit potent inhibition of tyrosinase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (13.33)18.7374
1990's0 (0.00)18.2507
2000's6 (40.00)29.6817
2010's7 (46.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.78

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.78 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.78)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (93.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetanilide
acetanilide: a phenylacetamide; use ACETANILIDES for the plural group meaning of the singular term. N-phenylacetamide : A member of the class of acetamides that is acetamide in which one of the hydrogens attached to the nitrogen is substituted by a phenyl group.		2.1110acetamides;
anilide		analgesic
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.1110carbohydrazideantitubercular agent;
drug allergen
1,2,4-triazole
1,2,4-triazole: RN given refers to 1H-1,2,4-triazole		7.08101,2,4-triazole
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.08101,2,3-triazole
prothionamide
Prothionamide: Antitubercular agent similar in action and side effects to ETHIONAMIDE. It is used mostly in combination with other agents.		2.1110pyridines
phenylthiourea
Phenylthiourea: Phenylthiourea is a THIOUREA derivative containing a phenyl ring. Depending on their genetic makeup, humans can find it either bitter-tasting or tasteless.. N-phenylthiourea : A member of the class of thioureas that is thiourea in which one of the hydrogens is replaced by a phenyl group. Depending on their genetic makeup, humans find it either very bitter-tasting or tasteless. This unusual property resulted in N-phenylthiourea being used in paternity testing prior to the advent of DNA testing.		2.1110thioureasEC 1.14.18.1 (tyrosinase) inhibitor
thiobenzamide
thiobenzamide: structure; hepatotoxin in rats		2.1110benzenes
thionicotinamide
[no description available]		2.1110
pyridine-2-carbothioamide
pyridine-2-carbothioamide: structure in first source		2.1110
ethionamide
Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.		2.1110pyridines;
thiocarboxamide		antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug
bilirubin
[no description available]		2.3920biladienes;
dicarboxylic acid		antioxidant;
human metabolite;
mouse metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Tuberculosis, Drug-Resistant
[description not available]		02.1110
Tuberculosis, Multidrug-Resistant
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.		02.1110
Cirrhoses, Experimental Liver
[description not available]		02.0210